Results 151 to 160 of about 142,317 (291)
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies [PDF]
, 2019 Yuan Liu, Xining Liao, Guixiu Shi
openalex +1 more source
Arthritis &Rheumatology, Accepted Article.Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti +13 more
wiley +1 more source
Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis
Arthritis &Rheumatology, Accepted Article.Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm +2 more
wiley +1 more source
Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)‐specific autoantibody repertoire [PDF]
, 2004 Emily K. Mathey +3 more
openalex +1 more source
A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus
Arthritis &Rheumatology, Accepted Article.Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen +14 more
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Objective Peripheral blood leukocyte telomere length (PBL‐TL) shortening is associated with systemic sclerosis related interstitial lung disease (SSc‐ILD). However, its association with other organ involvement, disease severity, and survival remains unclear.
Monica M. Yang +6 more
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo +15 more
wiley +1 more source